Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Novartis's total debt was $1.48B at Dec 31, 2025. For fiscal 2025 it was $1.48B, down 63.1% from the year before. The highest annual figure on record is $4.00B in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48B | -63.1% |
| FY2024 | Dec 31, 2024 | $4.00B | +42.0% |
| FY2023 | Dec 31, 2023 | $2.82B | -9.3% |
| FY2022 | Dec 31, 2022 | $3.10B | -11.8% |
| FY2021 | Dec 31, 2021 | $3.52B | +8.4% |
| FY2020 | Dec 31, 2020 | $3.25B | +19.4% |
| FY2019 | Dec 31, 2019 | $2.72B | -30.1% |
| FY2018 | Dec 31, 2018 | $3.89B | +270.2% |
| FY2017 | Dec 31, 2017 | $1.05B | +3.6% |
| FY2016 | Dec 31, 2016 | $1.01B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $1.48B | -58.1% |
| Q4 FY2024 | Dec 31, 2024 | $4.00B | +23.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.82B | +3.5% |
| Q4 FY2022 | Dec 31, 2022 | $3.10B | -20.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.52B | +234.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.25B | +220.3% |
| Q4 FY2019 | Dec 31, 2019 | $2.72B | – |
| Q4 FY2018 | Dec 31, 2018 | $3.89B | – |
| Q4 FY2017 | Dec 31, 2017 | $1.05B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.01B | – |
See a number that looks wrong?